Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.85 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.85 |
| ▸ | ADRB3 | P13945 | 12/20 | 0.85 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | DRD1 | P21728 | 2/20 | 0.60 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841558 | 0.92 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3837610 | 0.90 | ADRB2 (0.86) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL246986 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL335742 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL29798936 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL29390087 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3845327 | 0.90 | ADRB2 (0.83) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3837623 | 0.90 | ADRB2 (0.85) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL4385888 | 0.89 | ADRB2 (0.98) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3844729 | 0.89 | ADRB2 (0.82) | ADRB2ADRB1ADRB3DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-27 | — | — | US | disclosed |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB3, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 2/4885 |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.